A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
Diphtheria, Tetanus, Pertussis
About this trial
This is an interventional prevention trial for Diphtheria
Eligibility Criteria
Inclusion Criteria: Healthy male and female adults aged 19 - 55 on Visit 1 Those without clinically significant abnormalities on the screening test on Visit 1 Those with a confirmed BMI of 18.5 kg/m2 to less than 30 kg/m2 on Visit 1 Those who have heard a detailed explanation of the study and whose written consent to participate in the study was given voluntarily by themselves or their legal representatives Exclusion Criteria: Those who participated in other studies and took investigational products/ investigational vaccines within 6 months from Visit 1 Those who took tetanus toxoid (TT), tetanus-diphtheria (Td), tetanus-reduced diphtheria-acellular pertussis (Tdap) vaccine for adults, or other vaccines containing tetanus-diphtheria for adults within 5 years from Visit 1 Those who were vaccinated within 4 weeks from Visit 1 or who plan to receive vaccines other than the investigational vaccine from the participation in this study to Visit 5 Have had diphtheria, tetanus, pertussis, hepatitis B, polio, or invasive diseases caused by Haemophilus influenzae type b
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Test group
Control group
DTaP-HepB-IPV-Hib vaccine
DTaP-HepB-IPV-Hib vaccine